Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05686122
Other study ID # Pro00112397
Secondary ID 1R21CA273832
Status Recruiting
Phase N/A
First received
Last updated
Start date September 28, 2023
Est. completion date March 31, 2025

Study information

Verified date October 2023
Source Duke University
Contact Sarah A Kelleher, PhD
Phone 919-416-3405
Email sarah.kelleher@duke.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PainPac is innovative in its potential to integrate with healthcare systems through electronic medical records (EMRs). PainPac leverages technology to increase patient access to interventions and uses real-time assessment to improve care. PainPac is positioned to rapidly provide improved care through combining biological data (e.g., EMRs, patient collected) with behavioral data to dramatically improve outcomes. PainPac could track beneficial outcomes related to clinical pain scores (e.g., patients with scores 4-8 benefit) and intervention implementation could be based on this; a more advanced possibility is use of geospatial tracking to predict space/time where pain is likely to impact functioning and push an intervention strategy - behavioral or pharmacological. PainPac is designed for future transmission of data to EMRs to inform providers of patient status. This work will provide data to bypass traditional efficacy trials and move quickly to a large effectiveness trial.


Description:

The investigators will use a pilot RCT to examine PainPac feasibility, patient burden, engagement, acceptability, and initial pain-related outcomes, compared to a therapist led videoconference delivered behavioral pain intervention (PCST-Video) in colorectal cancer patients with pain. Investigators will use quantitative and qualitative data to optimize PainPac. Participants will complete assessments at pre-treatment (A1), post-treatment (A2; 4 weeks post-A1), and 1 month follow-up (A3; 1 month post-A2) (months 5-22). The pain management strategies are relevant and efficacious across cancer types. Due to the pilot nature of this work, investigators will enroll an opportunity sample of colorectal cancer patients. PainPac is a patient-focused intervention developed using cognitive-behavioral theory and empirically supported strategies to enhance patients' ability to manage their pain. PainPac is a mobile app available to participants on a smartphone or tablet. PainPac uses Social Cognitive Theory to promote behaviors to improve pain, self-efficacy for pain management, and pain-related quality of life indices. It also uses real-time data to personalize the intervention and messaging to participants. PainPac contains 4 modules, each including a skill that has shown efficacy for reducing pain in patients with cancer. Patients are prompted to complete one module each week for 4 weeks. The app also has interactive components to improve coping skills engagement. Participants randomized to PCST-Video will receive 4 behavioral cancer pain intervention sessions delivered by videoconferencing by a pain therapist in the medical center to the patient in their natural environment (e.g., home). Sessions will be scheduled weekly for 45-60 min and mimic in person sessions. PCST-Video session content is matches the PainPac skills modules described above. PCST-Video participants will complete assessments at the same intervals as PainPac participants. Aim 1: Test whether PainPac is feasible (primary aim), low burden, engaging, and acceptable. Aim 2: Examine the impact of PainPac on pain severity, pain interference, pain self-efficacy, and quality of life. Aim 3: Gather quantitative and qualitative post-treatment data on patients' preferences, barriers, and facilitators regarding PainPac to update and optimize PainPac for a future large randomized clinical effectiveness trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Stage I-IV Colorectal Cancer diagnosis - 18 years of age or older Exclusion Criteria: - Cognitive Impairment - Brain Metastases - Severe psychiatric condition (e.g., psychosis) that would contraindicate safe participation - Participation in behavioral pain management in the past 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
PainPac
Patient-focused behavioral pain intervention delivered via mobile application.

Locations

Country Name City State
United States Duke Cancer Institute Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility as measured by study accrual Reaching target accrual (N=60) within 15 months. 15 months
Primary Feasibility as measured by attrition <25% attrition by 1-month post-baseline. 1-month post-baseline assessment
Primary Feasibility as measured by the number of study baseline assessments completed Protocol adherence indicated by calculating the degree to which participants are willing/able to complete the study baseline assessment. 20 minutes
Primary Feasibility as measured by the number of post-study sessions assessments completed Protocol adherence indicated by calculating the degree to which participants are willing/able to complete the post-study sessions assessment. 20 minutes
Primary Feasibility as measured by the number of study 1-month follow up assessments completed Protocol adherence indicated by calculating the degree to which participants are willing/able to complete the 1-month follow up assessment. 20 minutes
Primary Feasibility of PainPac Includes protocol adherence indicated by calculating the degree to which participants are willing/able to complete the 4 PainPac skills modules or 4 PCST-Video sessions. 11 Weeks
Secondary Acceptability as measured by the Client Satisfaction Questionnaire. 10-item Client Satisfaction Questionnaire (CSQ). This questionnaire contains 10 items rated from 1=low acceptability to 4=high acceptability; scores are created by utilizing the Likert Scale to average Client Satisfaction Questionnaire answers resulting in a score range from 1-4. The participant will complete this acceptability questionnaire as part of the post-session follow up assessment. 20 minutes
Secondary Acceptability as measured by Atkinson's tool of mHealth innovations. Atkinson's tool will also be used to assess perceived attributes of mHealth innovations. Tool has 30 items about mHealth, participant indicates their level of agreement or disagreement on a 6-point Likert scale: l=strongly agree, 2=agree, 3=somewhat agree, 4=somewhat disagree. 5=disagree, and 6=strongly disagree. 20 minutes
Secondary PainPac Patient Preferences, Barriers, Facilitators, Attitudes, and Beliefs Post-intervention, measured together as one measure, patients will be asked 10 items modeled from labs previous work. Items will be answered on a 0-10 scale with 0=low preference, barrier, belief and 10=high preference, barrier, belief. Post-Intervention Survey, 20 minutes
Secondary Change in Computer Self-Efficacy Post-Intervention, 10 items on a 10 point scale from 0=not at all confident to 10=completely confident. Patients are asked 10 items regarding their confidence in ability to use technology (computer and smartphone app). Post-Intervention Survey, 20 minutes
Secondary Change in Pain Severity as Assessed With the Brief Pain Inventory (BPI) Pain will be assessed with the Brief Pain Inventory (BPI). Patients will rate their "worst", "least", "average", and "now" pain from 0=no pain to 10=worst pain imaginable. An average of the responses to these items is used to create a single pain severity score. 11 weeks
Secondary Pain Interference as Assessed With the Brief Pain Inventory (BPI) - Pain Interference Scale Pain interference will be assessed with the Brief Pain Inventory (BPI) - Pain Interference Scale. Patients will rate how much pain interfered with a variety of activities and mood states over the last 7 days from 0=does not interfere to 10=completely interferes. An average of the responses to these items is used to create a single pain severity score. 11 weeks
Secondary Change in Pain Self-Efficacy for Pain Management 5-item self-efficacy subscale of the Chronic Pain Self-Efficacy Scale. Items ask about patients' certainty about pain control, pain during activities, and reducing pain without extra medication using a 10=very uncertain to 100=very certain scale and averaged. The 10-item Computer Self-Efficacy Scale will be used to ask about patients' confidence in using technology to receive a behavioral pain intervention. 11 weeks
Secondary Change in Patient Burden 12-item measure developed in the lab through a NCI study examining burdens with accessing care after a cancer diagnosis. Patients will rate difficulty completing the intervention (PainPac modules or PCST-Video sessions) on a 1=not at all to 5=very much scale based on physical, emotional, financial burdens. A summated scale will be used to assess internal validity using Cronbach's alpha of 0.75. 11 Weeks
Secondary Engagement in Study Engagement is defined as the number of times/week participants log into PainPac and practice the skills. Engagement will be assessed based on app data and patient self-report. Patient Engagement will be assessed by electronic app data (e.g., PainPac weekly log-ins) and patient self-report defined as the number of times per week they practice the coping skills. >3 times/week will serve as the benchmark; if participants log into PainPac and/or practice the coping skills <3 times/week, PainPac will not be considered engaging. 11 Weeks
Secondary Change in Quality of Life Centers for Disease Control Health Related Quality of Life 14-item measure. This measure assesses healthy days in the last month and activity limitations and symptoms. 11 Weeks
Secondary Change in PROMIS - Emotional Distress (Depression) Short Form Post-intervention and 1-month follow up, 8 items on a 5 point scale from 1=never, 2=rarely, 3=sometimes, 4=often, 5=always. Patients are asked 8-items regarding "in the past 7 days I felt..." to assess their emotional distress levels. 11 weeks
See also
  Status Clinical Trial Phase
Suspended NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Not yet recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A